4D Molecular Therapeutics, Inc. (FDMT)

US — Healthcare Sector
Peers: TCRR  RVMD  BDTX  BCEL  PASG  IPSC  EWTX  CCCC  MLYS  CGEM  BMEA  STOK  AKRO  FIXX  GOSS  REPL  NVCT  LYRA  KRON 

Automate Your Wheel Strategy on FDMT

With Tiblio's Option Bot, you can configure your own wheel strategy including FDMT - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.

Start Your Free Trial Now

Key Metrics & Ratings

  • symbol FDMT
  • Rev/Share 0.0002
  • Book/Share 8.4264
  • PB 0.445
  • Debt/Equity 0.0508
  • CurrentRatio 12.3635
  • ROIC -0.4112

 

  • MktCap 173717250.0
  • FreeCF/Share -2.7535
  • PFCF -1.1318
  • PE -1.1848
  • Debt/Assets 0.0463
  • DivYield 0
  • ROE -0.3327

 

  • Rating B-
  • Score 3
  • Recommendation Neutral
  • P/E Score 1
  • DCF Score 4
  • P/B Score 5
  • D/E Score 3

Recent Analyst Ratings

Type Ticker Analyst Firm Previous Rating Current Rating Previous Price Target Current Price Target Date
Downgrade FDMT BMO Capital Markets Outperform Market Perform $40 $15 Jan. 13, 2025
Downgrade FDMT Cantor Fitzgerald Overweight Neutral -- -- Sept. 23, 2024

News

4DMT Announces RMAT Designation Granted by FDA for 4D-150 for DME
FDMT
Published: May 01, 2025 by: GlobeNewsWire
Sentiment: Neutral

EMERYVILLE, Calif., May 01, 2025 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment paradigms and provide unprecedented benefits to patients, today announced that the U.S. Food and Drug Administration (FDA) has granted the Regenerative Medicine Advanced Therapy (RMAT) designation to 4D-150 for the treatment of diabetic macular edema (DME).

Read More
image for news 4DMT Announces RMAT Designation Granted by FDA for 4D-150 for DME
4DMT to Participate in Upcoming Investor Conferences
FDMT
Published: March 27, 2025 by: GlobeNewsWire
Sentiment: Neutral

EMERYVILLE, Calif., March 27, 2025 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment paradigms and provide unprecedented benefits to patients, today announced that management will participate in a fireside chat at the upcoming RBC Capital Markets 2025 Ophthalmology Conference being held virtually on April 3-4, 2025. Members of the management team will also be available for one-on-one meetings.

Read More
image for news 4DMT to Participate in Upcoming Investor Conferences
4DMT to Participate in Upcoming Investor Conferences
FDMT
Published: February 19, 2025 by: GlobeNewsWire
Sentiment: Neutral

EMERYVILLE, Calif., Feb. 19, 2025 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading clinical-stage company focused on unlocking the full potential of genetic medicines to treat large market diseases, today announced that management will participate in fireside chats at upcoming investor conferences in March. Members of the management team will also be available for one-on-one meetings.

Read More
image for news 4DMT to Participate in Upcoming Investor Conferences
4D Molecular Therapeutics: A Smart Bet On Long-Term VEGF Suppression
FDMT
Published: February 18, 2025 by: Seeking Alpha
Sentiment: Positive

4D Molecular Therapeutics is undervalued, with its lead candidate 4D-150 showing potential to disrupt the anti-VEGF treatment paradigm for retinal diseases. The company has a strong cash position of $551 million, funding operations through 2027, allowing it to avoid immediate financing needs. 4D-150's Phase 2 data shows reduced need for supplemental injections, positioning it as a long-term, durable treatment for wet AMD and DME.

Read More
image for news 4D Molecular Therapeutics: A Smart Bet On Long-Term VEGF Suppression
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of 4D Molecular Therapeutics, Inc. - FDMT
FDMT
Published: February 11, 2025 by: PRNewsWire
Sentiment: Neutral

NEW YORK , Feb. 11, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of 4D Molecular Therapeutics, Inc. ("4D" or the "Company") (NASDAQ: FDMT). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.

Read More
image for news INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of 4D Molecular Therapeutics, Inc. - FDMT

About 4D Molecular Therapeutics, Inc. (FDMT)

  • IPO Date 2020-12-11
  • Website https://www.4dmoleculartherapeutics.com
  • Industry Biotechnology
  • CEO Dr. David H. Kirn M.D.
  • Employees 227

4D Molecular Therapeutics, Inc., a clinical-stage gene therapy company, develops product candidates using its adeno-associated viruses vectors. It develops a portfolio of gene therapy product candidates focuses in three therapeutic areas: ophthalmology, cardiology, and pulmonology. The company has three product candidates that are in clinical trials: 4D-125 that is in a Phase 1/2 clinical trial for the treatment of X-linked retinitis pigmentosa; 4D-110 that is in a Phase 1/2 clinical trial for the treatment of choroideremia; and 4D-310, which is in a Phase 1/2 clinical trial for the treatment of Fabry disease. Its two IND candidates are 4D-150 for the treatment of wet age-related macular degeneration and 4D-710 for the treatment of cystic fibrosis lung disease. 4D Molecular Therapeutics, Inc. has research and collaboration arrangements with uniQure; CRF; Roche; and CFF. The company was founded in 2013 and is headquartered in Emeryville, California.4D Molecular Therapeutics, Inc., a clinical-stage gene therapy company, develops product candidates using its adeno-associated viruses vectors. It develops a portfolio of gene therapy product candidates focuses in three therapeutic areas: ophthalmology, cardiology, and pulmonology. The company has three product candidates that are in clinical trials: 4D-125 that is in a Phase 1/2 clinical trial for the treatment of X-linked retinitis pigmentosa; 4D-110 that is in a Phase 1/2 clinical trial for the treatment of choroideremia; and 4D-310, which is in a Phase 1/2 clinical trial for the treatment of Fabry disease. Its two IND candidates are 4D-150 for the treatment of wet age-related macular degeneration and 4D-710 for the treatment of cystic fibrosis lung disease. 4D Molecular Therapeutics, Inc. has research and collaboration arrangements with uniQure; CRF; Roche; and CFF. The company was founded in 2013 and is headquartered in Emeryville, California.